Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Trump’s Legacy Versus ‘March In’ Rights

Jan 23 2021

• By Michael McCaughan

Related Content

Biden Regulatory Freeze May Pause Sunset Rule, Medicare Rebate, Medicaid Line Extension Regs

Jan 20 2021

Building A Wall? The Plan To End “March In” Threat To US Drug Patents

Apr 24 2019

NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns

Apr 20 2016

Biden’s HHS Pick Sought ‘March In’ Rights For Veklury; Targeted AbbVie ‘Pay For Delay’ Tactics

Dec 09 2020

‘March In’ Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?

Sep 24 2020

Related Companies

Gilead Sciences, Inc.

Additional Topics

United States Elections Intellectual Property Legal Issues Policy Politics BioPharmaceutical

More from Elections

More from Legislation

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window